As for results of first 5 months 2017, Grammidin® reached 1 place in the segment of the pills from the pain in the throat.
According to the IMS Health agency’s audit for the first 5 months 2017 (Jan-May), Grammidin® is №1 in value terms and occupied 18,7% of market share in the segment of the pills from the pain in the throat.
Such leadership was achieved for the first time by Grammidin® brand.
Anfinogenova Lesya, Group product manager, BU “Cold & Flu” at Valenta Pharm: “Sales results of Grammidin® is the reflection of customers attitude towards the Grammidin® medicine and an indirectly confirmation the choice of doctors, medical specialists and patients. We will work on strengthening and increasing leader positions of Grammidin in a segment of means for treatment of infectious and inflammatory diseases of a throat”.